Brian Druker Pitches for LLS in New Video

The Leukemia & Lymphoma Society is bringing out the big guns for its latest fundraising campaign.

Having directed hundreds of millions of dollars to research into cures for blood cancers and related disorders, the Leukemia & Lymphoma Society has several jewels in its crown – researchers and research trials it has helped fund.

Funding for LLS

Few have the profile and the pedigree of Brian Druker – the man chiefly responsible for Gleevec, the life-saving drug for people with chronic lymphocytic leukemia. Druker received funding from the LLS when he needed it to carry out translational research for the early phases of Gleevec.

It is little surprise then to find Druker being featured in a new fundraising video for the LLS:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap